House Expected To Eliminate Earmarks, give NCI $2 Billion For FY94, A $40 Million Increase
In Brief: Gene Therapy For ADA Deficiency Moves forward With Stem Cell Treatment In Caif. And At NIH
ACS Initiates Cage In Approach to Study Of alternative Methods
DT Board Oks RFAs In Surgery, HIV, Breast Cancer
Patient Costs In Trials Should Be Paid In Any Reform Plan, DCT Board Write To Shalala
FDA Simplifies Reporting Of Adverse Events
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
